Tixagevimab

Overview of attention for article published in Transplant International, December 2022

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 10,086 followers.

RT @FrontPartners: The results of using #Sotrovimab, and the need to adapt PrEP based on pre-dominant SARS-CoV-2 variant characteristics.…

The results of using #Sotrovimab, and the need to adapt PrEP based on pre-dominant SARS-CoV-2 variant characteristics. https://t.co/z1gpWyfCRI From Stiasny, Heinzel, Reindl-Schwaighofer, @RainerOberbauer et al. from @MedUni_Wien #COVID19 #TransplantTwi

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.